Rosin acid derivative as well as preparation method and application thereof

By developing and optimizing rosin acid derivatives, using acylation, amide condensation and alkylation reactions, the problem of drug crossing the blood-brain barrier in brain glioma treatment was solved, and significant inhibition of glioma cells was achieved and The permeability of the blood-brain barrier has been improved, significantly improving the therapeutic effect and safety.

CN119080704AActive Publication Date: 2024-12-06GUANGDONG PHARMA UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410456267.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-16
Publication Date
2024-12-06
Estimated Expiration
2044-04-16

AI Technical Summary

Technical Problem

The existing treatment drugs for glioma are difficult to cross the blood-brain barrier, resulting in poor treatment results. Most patients relapse after treatment, and chemotherapy drugs are highly resistant to drugs and have low median survival.

Method used

A rosin acid derivative was developed to prepare compounds with anti-brain glioma effects through reactions such as acylation, amide condensation, and alkylation, and to improve the permeability of the blood-brain barrier by optimizing its structure.

Benefits of technology

Rosin acid derivatives significantly inhibit glioma cell proliferation, have good anti-brain glioma treatment effect, and show significant efficacy at lower concentrations, and their pKa range is 6.2 to 7.2, enhancing blood Brain barrier permeability reduces toxic side effects on normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080704A_ABST
    Figure CN119080704A_ABST
Patent Text Reader

Abstract

The invention discloses a abietic acid derivative and a preparation method and application thereof.The abietic acid derivative has remarkable anti-proliferative activity on glioma cells, can achieve the remarkable anti-brain glioma proliferation effect under the low-concentration condition, has the good tumor treatment effect and can be used for preparing a medicine for treating brain glioma proliferation. The compound with prominent activity has low hepatotoxicity, and has an anti-proliferation effect on brain glioma cells in a time and concentration dependent manner; moreover, the pKa of the representative abietic acid derivative is in the range of 6.2-7.2, and the representative abietic acid derivative has better blood-brain barrier permeability and is beneficial to entering the brain to exert efficacy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of natural products and pharmaceutical chemistry, and in particular to a rosin acid derivative and a preparation method and application thereof. Background Art

[0002] Gliomas are malignant brain tumors that usually require comprehensive treatments such as surgical resection, radiotherapy and chemotherapy. However, due to its complex etiology and pathogenesis, BBB, BBTB and increasing drug resistance, current drug treatments still have certain limitations. In recent years, no new clinically marketed drugs for the treatment of gliomas have appeared, and most drugs are still in the clinical trial stage. EGFR gene changes (including mutations, rearrangements, alternative splicing and focal amplification) are widely present in 57% of GBM (a common high-grade malignant tumor in glioma) patients. Although some EGFR inhibitors that have been marketed or are in clinical trials have a certain effect on GBM patients, their therapeutic effects are still greatly limited due to the low concentration of drugs that can reach the lesions through the BBB. Chemotherapy drugs such as temozolomide (TMZ), cisplatin and carmustine are important clinical adjuvant treatment drugs. Even with standardized treatment, almost all GBM patients will relapse. This is because it is difficult for surgeons to completely remove highly invasive glioma cells without affecting normal brain function. These cells have the characteristics of rapid proliferation, anti-apoptosis and rapid metastasis. Therefore, postoperative recurrence is one of the biggest challenges in treating GBM. Most GBM patients show insensitivity to radiotherapy and are prone to chemotherapy after recurrence. Due to the drug resistance caused by chemotherapy, the median survival rate of GBM patients is about 15 months, and the treatment effect is not ideal. For this reason, it is crucial to design and develop drugs that can penetrate the BBB to reach the tumor location and have low toxic side effects on normal cells. How to effectively improve the blood-brain barrier permeability of drugs and reduce drug toxicity and side effects has been driving people to develop new anti-glioma drugs.

[0003] Natural products have a wide range of structural diversity and pharmacological pleiotropy. They are an important source for discovering lead compounds and have a profound impact on drug development. Natural products and their molecular skeletons are valuable starting points for drug discovery and can provide innovations for new drug development. A large number of literature shows that rosin acid derivatives have a wide range of biological activities and have good anti-proliferative activity against various types of tumor cells. In addition, rosin acid derivatives also have good lipid solubility. These characteristics make rosin acid derivatives useful as lead compounds for the development of anti-glioma drugs for further research. At present, there is still a lack of effective drugs for the treatment of gliomas. Therefore, it is still necessary to develop more effective drugs to inhibit gliomas. Summary of the invention

[0004] In order to overcome the defects and insufficiency of existing drugs for treating glioma, an embodiment of the present invention provides a rosin acid derivative. The natural products abietic acid (AA) and dehydroabietic acid (DHAA) are tricyclic diterpenoid oxygen-containing compounds obtained from rosin or disproportionated rosin, and have high safety. Based on the structures of abietic acid and dehydroabietic acid, a series of compounds with anti-glioma efficacy have been developed.

[0005] A rosin acid derivative, wherein the rosin acid derivative has a structure of Formula I or Formula II:

[0006]

[0007] in,

[0008] R is

[0009] R1 is selected from hydrogen, halogen, methoxy or methyl;

[0010] R2 is selected from hydrogen, halogen, methoxy or methyl;

[0011] R3 is selected from hydrogen, methyl, methoxy or difluoromethoxy.

[0012] Preferably, R is one of the following:

[0013]

[0014]

[0015] For example, the rosin acid derivative has any of the following structures:

[0016]

[0017]

[0018] Preferably, the pharmaceutically acceptable salts obtained by reacting the rosin acid derivatives with acids are also within the protection scope of the present invention, wherein the acid is hydrochloric acid, nitric acid, sulfuric acid or trifluoroacetic acid, phosphoric acid, acetic acid, or carbonic acid.

[0019] Another aspect of the present invention provides a method for preparing abietic acid derivatives, comprising the following steps:

[0020]

[0021] S1, using AA as a starting material, undergoing an acylation reaction in the presence of an acylating agent and a polar organic solvent to obtain compound 1, and then undergoing an amide condensation reaction with one of the anilinopyrimidine compounds 2a-2h in the presence of an acid-binding agent and a polar organic reagent to obtain compounds A1-A8;

[0022]

[0023] S2, using DHAA as a starting material, an acylation reaction is carried out under the action of an acylating agent and a polar organic solvent to obtain compound 3, and then an amide condensation reaction is carried out with one of the anilinopyrimidine compounds 2a-2h under the action of an acid-binding agent and a polar organic reagent to obtain compounds B1-B8;

[0024]

[0025] S3, using AA as a starting material, an alkylation reaction is carried out under the action of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, and then an N-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and one of aniline compounds 5a-5h to obtain compounds A9-A16;

[0026]

[0027] S4, using DHAA as a starting material, an alkylation reaction is carried out under the action of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 6, and then an N-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and one of aniline compounds 5a-5h to obtain compounds B9-B16;

[0028]

[0029] S5, using AA as a starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, and then an S-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and a pyridine compound 7 to obtain compound A17;

[0030]

[0031] S6, using DHAA as a starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 6, and then an S-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and a pyridine compound 7 to obtain compound B17;

[0032]

[0033] S7, using AA as a starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, which is then subjected to an S-alkylation reaction with an alkaline reagent, a polar organic reagent and benzimidazole compounds 8a-8d to obtain compounds A18-A21;

[0034]

[0035] S8. Using DHAA as the starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, which is then subjected to an S-alkylation reaction with an alkaline reagent, a polar organic reagent and benzimidazole compounds 8a-8d to obtain compounds B18-B21.

[0036] Furthermore, the acylating agent is selected from one or more of oxalyl chloride, thionyl chloride and diphenylcarbamoyl chloride.

[0037] Furthermore, the acid binding agent is selected from one or more of triethylamine, pyridine and N,N-diisopropylethylamine.

[0038] Furthermore, the polar organic solvent is selected from one or more of N,N-dimethylformamide and dichloromethane.

[0039] Furthermore, the alkaline agent is selected from one or more of potassium carbonate, triethylamine and N,N-diisopropylethylamine.

[0040] Preferably, the equivalent ratio of AA or DHAA to the acylating agent is 1:1.5-1.8; the acylation reaction occurs at a reaction temperature of 0°C to room temperature to produce compound 1 or compound 3.

[0041] Preferably, the compound 1 or compound 3 and the compound One of the above undergoes an amide condensation reaction, the reaction temperature is room temperature, and the reaction time is 16-18 hours.

[0042] Preferably, the equivalent ratio of AA or DHAA to 1,2-dibromoethane is 1:2-2.5; and the alkylation reaction occurs at room temperature to produce compound 4 or compound 6.

[0043] Another aspect of the embodiments of the present invention further provides the use of the rosin acid derivatives or pharmaceutically acceptable salts thereof in the preparation of anti-glioma drugs.

[0044] Preferably, the cancer includes glioma caused by abnormal expression of epidermal growth factor receptor and / or its mutants.

[0045] In addition, the present invention also claims a pharmaceutical composition comprising one or more of the rosin acid derivatives, their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, tautomers and stereoisomers or their prodrugs.

[0046] Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable excipients and / or carriers.

[0047] Preferably, the excipients include at least one of the following substances: solvents, propellants, solubilizers, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-chelating agents, integrators, penetration enhancers, pH regulators, buffers, plasticizers, solubilizers, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, release agents, flocculants and deflocculating agents, filter aids, and release retardants.

[0048] The pharmaceutical composition of the present invention can be made into various dosage forms: classified by the dispersion system of the dosage form, specifically, it can be made into the following preparations: solution type, colloidal solution type, emulsion type, suspension type, gas dispersion type, microparticle dispersion type, solid dispersion type; classified by form, specifically, it can be made into the following dosage forms: liquid dosage forms (such as aromatic water preparations, solutions, injections, mixtures, lotions, ointments, etc.), solid dosage forms (such as powders, pills, tablets, films, etc.), semi-solid dosage forms (such as ointments, suppositories, pastes, etc.).

[0049] The present invention has the following beneficial effects:

[0050] The present invention provides a rosin acid derivative. Experiments have shown that the rosin acid derivative has significant anti-proliferation effect on glioma cells, can achieve significant anti-glioma proliferation effect under low concentration conditions, and has good anti-glioma therapeutic effect; and the pKa of the representative rosin acid derivative is within the range of 6.2 to 7.2, has good blood-brain barrier permeability, and is conducive to entering the brain to exert its drug effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0052] Figure 1 The cell survival rate of U87MG cells after being treated with the compound of Example 44 of the present invention at different concentrations and for different time periods.

[0053] Figure 2 This is a pH-VKOH (μL) curve of the compound of Example 45 of the present invention. DETAILED DESCRIPTION

[0054] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0055] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0056] Example 1

[0057] Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-N-(4-phenylamino)pyrimidin-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A1)

[0058] 1. N4-phenylpyrimidine-2,4-diamine (2a)

[0059]

[0060] Weigh 4-amino-6-chloropyrimidine (1 g, 7.72 mmol) and aniline (1.08 g, 11.58 mmol), add isopropanol (10 mL), add 2 drops of concentrated HCl at room temperature, and reflux at 80°C for 2 h. After the reaction is complete as monitored by thin layer plate, quench with saturated NaHCO3, extract with EAC, wash the organic phase with saturated NaCl, dry with anhydrous Na2SO4, and separate and purify the concentrated organic mixture by silica gel column chromatography to obtain a white solid 2a with a yield of 85%.

[0061] 1H NMR (400MHz, DMSO-d6) δ9.06 (s, 1H), 7.79 (d, J = 5.7Hz, 1H), 7.70 (d, J = 7.4Hz, 2H ),7.31–7.21(m,2H),6.94(t,J=7.3Hz,1H),6.17(s,2H),5.99(d,J=5.7Hz,1H).

[0062] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-N-(4-phenylamino)pyrimidin-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A1)

[0063]

[0064] To a mixed solution of dichloromethane (25 mL) containing rosin acid (2 g, 6.61 mmol) was slowly added dropwise oxalyl chloride (1.26 g, 9.92 mmol) under ice bath conditions, and then 1-2 drops of N,N-dimethylformamide were added dropwise, and the mixture was transferred to room temperature and reacted under anhydrous conditions for 5 h. After 5 h, the solvent was evaporated under reduced pressure to obtain a yellow-brown oil, and anhydrous dichloromethane (10 mL) was added to obtain a yellow-brown rosin acid chloride for standby use. Subsequently, triethylamine (0.57 g, 5.61 mmol) was added to DCM containing the synthesized intermediate 2a (0.615 g, 3.30 mmol), and the mixture was reacted at room temperature for 15 min, and then the prepared rosin acid chloride was slowly added dropwise under ice bath conditions, and the mixture was transferred to room temperature and continued to react under anhydrous conditions for 16 h. After the reaction was completed by monitoring with a thin layer plate, the reaction solution was concentrated, H2O and EAC were added for extraction, the organic phase was washed with saturated NaCl, and dried with anhydrous Na2SO4, and then the concentrated organic mixture was separated and purified by silica gel column chromatography to obtain the final product A1. The yield was 28%, mp: 90.0-91.4°C.

[0065] 1H NMR (400MHz, DMSO-d6) δ9.61 (s, 1H), 8.12 (d, J = 5.8Hz, 1H), 7.89 (d, J = 5.0Hz, 2H ),7.28(t,J=7.9Hz,2H),6.98(t,J=7.4Hz,1H),6.50(d,J=5.8Hz,1H),5.72(s,1 H),5.32(d,J=4.5Hz,1H),2.25–2.01(m,4H),1.84(d,J=58.5Hz,6H),1.58(d,J= 12.8Hz, 5H), 1.26 (s, 3H), 0.96 (dd, J=6.8, 1.7Hz, 6H), 0.79 (s, 3H); ESI-MS: m / z calcdfor C30H38N4O[M+H]+:471.30,found 471.5.

[0066] Example 2

[0067] Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-fluorophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A2)

[0068] 1. Synthesis of N4-(4-fluorophenyl)pyrimidine-2,4-diamine (2b)

[0069]

[0070] Compound 2b was prepared by referring to the method of compound 2a to obtain a light yellow solid 2b with a yield of 81%.

[0071] 1H NMR (400MHz, DMSO-d6) δ9.11 (s, 1H), 7.79 (d, J = 5.7Hz, 1H), 7.72 (dd, J = 9.0, 4.9Hz, 2H), 7.09 (t, J = 8.9Hz, 2H), 6.21 (s, 2H), 5.95 (d, J = 5.7Hz, 1H).

[0072] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-fluorophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A2)

[0073]

[0074] The synthesis of compound A2 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A2 with a yield of 35% and mp: 114.6-115.5°C.

[0075] 1H NMR (400MHz, DMSO-d6) δ9.62(s,1H),9.57(s,1H),8.12(d,J=5.8Hz,1H),7.93(dd,J=9.1,4.9Hz,2H),7.10(t,J=8.9Hz,2H),6.46(d,J=5.9Hz,1H) ,5.72(s,1H),5.33(d,J=4.9Hz,1H),2.19(td,J=12.7,12.0,5.6Hz,2H), 2.09–1.93(m,4H),1.90–1.68(m,5H),1.59(d,J=26.1Hz,4H),1.26(s,3H ),0.97(dd,J=6.8,1.7Hz,6H),0.79(s,3H);13CNMR(101MHz,DMSO-d6)δ176.55,160.70,157.88,156.17,144.79,136.83,135.49,122.92,121.50 ,121.11,115.70,115.48,102.90,50.64,47.52,44.44,37.44,36.25,34 .74,34.65,27.41,25.33,22.40,21.79,21.53,21.20,17.32,14.41; 19F NMR (376MHz, DMSO-d6) δ-121.10; ESI-MS: m / z calcd for C30H37FN4O[M+H]+: 489.65, found 489.5.

[0076] Example 3

[0077] Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-chlorophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A3)

[0078] 1. Synthesis of N4-(4-chlorophenyl)pyrimidine-2,4-diamine (2c)

[0079]

[0080] Compound 2c was prepared by referring to the method of compound 2a to obtain white solid compound 2c with a yield of 83%.

[0081] 1H NMR (400MHz, DMSO-d6) δ9.26 (s, 1H), 7.83 (d, J = 5.7Hz, 1H), 7.78 (d, J = 8.9Hz, 2H), 7.29 (d, J = 8.9Hz, 2H), 6.29 (s, 2H), 5.99 (d, J = 5.7Hz, 1H).

[0082] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-chlorophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A3)

[0083]

[0084] The synthesis of compound A3 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A3 with a yield of 31% and mp: 133.8-134.8°C.

[0085] 1H NMR (400MHz, DMSO-d6) δ9.75(s,1H),9.66(s,1H),8.15(d,J=5.8Hz,1H),7.98(d,J =8.9Hz,2H),7.30(d,J=8.8Hz,2H),6.49(d,J=5.8Hz,1H),5.72(s,1H),5.32(d,J= 5.0Hz,1H),2.37–2.11(m,3H),2.05(d,J=18.0Hz,2H),1.96–1.69(m,6H),1.57(d, J=12.7Hz, 4H), 1.26 (s, 3H), 0.97 (dd, J=6.8, 1.8Hz, 6H), 0.79 (s, 3H); ESI-MS: m / z calcdfor C30H37ClN4O[M+H]+:505.27, found 505.4.

[0086] Example 4

[0087] Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-bromophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A4)

[0088] 1. Synthesis of N4-(4-bromophenyl)pyrimidine-2,4-diamine (2d)

[0089]

[0090] Compound 2d was prepared by referring to the method of compound 2a to obtain yellow solid compound 2d with a yield of 72%.

[0091] 1H NMR (400MHz, DMSO-d6) δ9.22 (s, 1H), 7.83 (d, J = 5.7Hz, 1H), 7.73 (d, J = 8.9Hz, 2H), 7.41 (d, J = 8.8Hz, 2H), 6.24 (s, 2H), 6.01 (d, J = 5.7Hz, 1H).

[0092] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-bromophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A4)

[0093]

[0094] The synthesis of compound A4 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A4 with a yield of 30% and mp: 120.4-122.6°C.

[0095] 1H NMR (400MHz, DMSO-d6) δ9.75 (s, 1H), 9.67 (s, 1H), 8.16 (d, J = 5.7Hz, 1H), 7.93 (d ,J=8.9Hz,2H),7.43(d,J=8.7Hz,2H),6.50(d,J=5.8Hz,1H),5.72(s,1H),5.32( d,J=5.0Hz,1H),2.41–2.11(m,3H),2.04(d,J=14.3Hz,2H),1.95–1.72(m,5H),1 .57(d,J=12.4Hz,5H),1.26(s,3H),0.97(dd,J=6.9,1.7Hz,6H),0.79(s,3H); 13C NMR(101MHz,Chloroform-d)δ176.34,161.28,157.25,156.75,145.35,137.29,135.52,132.44,123.54,122.37,120.34,11 7.44,50.97,48.03,45.77,38.16,37.50,34.90,34.75,27.42,25.47,22.50,21.42,20.85,18.35,17.14,14.16; ESI-MS:m / z calcd for C30H37BrN4O[M+H]+:549.22, found 549.3.

[0096] Example 5

[0097] Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-(4-iodophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A5)

[0098] 1. Synthesis of N4-(4-iodophenyl)pyrimidine-2,4-diamine (2e)

[0099]

[0100] Compound 2e was prepared by referring to the method of compound 2a to obtain yellow solid compound 2e with a yield of 52%.

[0101] 1H NMR (400MHz, DMSO-d6) δ9.21 (s, 1H), 7.83 (d, J = 5.7Hz, 1H), 7.66–7.46 (m, 4H), 6.25 (s, 2H), 6.01 (d, J = 5.7Hz, 1H).

[0102] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-N-(4-(4-iodophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A5)

[0103]

[0104] The synthesis of compound A5 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A5 with a yield of 22% and mp: 96.4-98.1°C.

[0105] 1H NMR (400MHz, DMSO-d6) δ9.75 (s, 1H), 9.67 (s, 1H), 8.16 (d, J = 5.7Hz, 1H), 7.93 (d ,J=8.9Hz,2H),7.43(d,J=8.7Hz,2H),6.50(d,J=5.8Hz,1H),5.72(s,1H),5.32( d,J=5.0Hz,1H),2.41–2.11(m,3H),2.04(d,J=14.3Hz,2H),1.95–1.72(m,5H),1 .57(d,J=12.4Hz,5H),1.26(s,3H),0.97(dd,J=6.9,1.7Hz,6H),0.79(s,3H); 13C NMR(101MHz,Chloroform-d)δ176.34,161.28,157.25,156.75,145.35,137.29,135.52,132.44,123.54,122.37,120.34,11 7.44,50.97,48.03,45.77,38.16,37.50,34.90,34.75,27.42,25.47,22.50,21.42,20.85,18.35,17.14,14.16; ESI-MS:m / z calcd for C30H37BrN4O[M+H]+:549.22, found 549.3.

[0106] Example 6

[0107] Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-N-(4-p-tolylamino)pyrimidin-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A6)

[0108] 1. Synthesis of N4-(p-tolyl)pyrimidine-2,4-diamine (2f)

[0109]

[0110] Compound 2f was prepared by referring to the method of compound 2a to obtain white solid compound 2f with a yield of 68%.

[0111] 1H NMR (400MHz, DMSO-d6) δ8.97 (s, 1H), 7.76 (d, J = 5.7Hz, 1H), 7.56 (d, J = 8.2Hz ,2H),7.07(d,J=8.1Hz,2H),6.15(s,2H),5.95(d,J=5.7Hz,1H),2.24(s,3H).

[0112] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-N-(4-p-tolylamino)pyrimidin-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A6)

[0113]

[0114] The synthesis of compound A6 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A6 with a yield of 31% and mp: 107.3-108.9°C.

[0115] 1H NMR(400MHz,DMSO-d6)δ9.52(s,1H),8.09(d,J=5.8Hz,1H),7.75(d,J=7.8Hz,2H), 7.09(d,J=8.1Hz,2H),6.45(d,J=5.8Hz,1H),5.72(s,1H),5.33(d,J=4.4Hz,1H),2 .25(s,3H),2.17(dt,J=12.5,6.0Hz,2H),2.10–1.90(m,5H),1.87–1.74(m,4H),1. 57(d,J=12.6Hz,4H),1.25(s,3H),0.96(d,J=6.8Hz,6H),0.78(s,3H); ESI-MS:m / z calcdfor C31H40N4O[M+H]+:485.32, found 485.5.

[0116] Example 7

[0117] Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-N-(4-methoxyphenylamino)pyrimidin-2-yl)-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A7)

[0118] 1. Synthesis of N4-(p-methoxyphenyl)pyrimidine-2,4-diamine (2 g)

[0119]

[0120] The synthesis of compound 2g was carried out by referring to the synthesis method of compound 2a to obtain yellow solid compound 5g with a yield of 88%.

[0121] 1H NMR (400MHz, DMSO-d6) δ 8.85 (s, 1H), 7.74 (d, J = 5.7Hz, 1H), 7.54 (d, J = 9.0Hz, 2H), 6.92–6.80 (m, 2H), 6.04 (s, 2H), 5.91 (d, J = 5.7Hz, 1H), 3.73 (s, 3H).

[0122] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-N-(4-methoxyphenylamino)pyrimidin-2-yl)-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A7)

[0123]

[0124] The synthesis of compound A7 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A7 with a yield of 15% and mp: 105.4-107.5°C.

[0125] 1H NMR (400MHz, DMSO-d6) δ9.52(s,1H),9.44(s,1H),8.06(d,J=5.9Hz,1H),7.77(d,J=8.0Hz,2H),6.86(d,J=8.9Hz,2H),6.40(d,J=5.9Hz,1H),5.72(s ,1H),5.34(s,1H),3.73(s,3H),2.28–2.01(m,4H),1.99–1.73(m,6H),1.7 2–1.34(m,5H),1.26(s,3H),0.97(dd,J=6.8,1.7Hz,6H),0.79(s,3H); 13C NMR(101MHz,Chloroform-d)δ162.69,157.70,145.21,130.36,125.63,122.43,120.47,114.79,99.05,55.55,50. 91,48.06,45.62,38.07,37.33,34.90,34.74,27.42,25.45,22.50,21.41,20.85,18.38,17.09,14.16; ESI-MS:m / z calcd for C31H40N4O2[M+H]+:501.32, found 501.4.

[0126] Example 8

[0127] Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-N-(m-tolylamino)pyrimidin-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A8)

[0128] 1. Synthesis of N4-(m-tolyl)pyrimidine-2,4-diamine (2h)

[0129]

[0130] The synthesis of compound 2h was carried out by referring to the synthesis method of compound 2a to obtain yellow solid compound 2h with a yield of 53%.

[0131] 1H NMR (400MHz, DMSO-d6) δ9.01(s,1H),7.79(d,J=5.7Hz,1H),7.55(d,J=8.2Hz,1H),7.48(s,1H) ,7.14(t,J=7.8Hz,1H),6.76(d,J=7.5Hz,1H),6.21(s,2H),5.99(d,J=5.7Hz,1H),2.29(s,3H).

[0132] 2. Synthesis of (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-N-(m-tolylamino)pyrimidin-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide (A8)

[0133]

[0134] The synthesis of compound A8 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid compound A8 with a yield of 33% and mp: 116.-113.0°C.

[0135] 1H NMR (400MHz, DMSO-d6) δ9.64(s,1H),9.53(s,1H),8.11(d,J=5.8Hz,1H),7.93(s,1H),7.54(d ,J=7.9Hz,1H),7.15(t,J=7.9Hz,1H),6.79(d,J=7.5Hz,1H),6.48(d,J=5.9Hz,1H),5.71(s,1 H),5.32(d,J=5.1Hz,1H),2.29(s,3H),2.19(dt,J=12.9,6.3Hz,2H),1.99(s,5H),1.90–1.74 (m,4H),1.58(d,J=13.4Hz,4H),1.26(s,3H),0.96(d,J=6.8Hz,6H),0.79(s,3H); ESI-MS:m / z calcd for C31H40N4O[M+H]+:485.32, found 485.4.

[0136] Example 9

[0137] Synthesis of 2-(phenylamino)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A9)

[0138] Synthesis of 2-bromoethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (4)

[0139]

[0140] Weigh rosin acid (2g, 6.61mmol) and potassium carbonate (2.74g, 19.8mmol), add DMF (6mL), then add 1,2-dibromoethane (2.48g, 13.22mmol), and react at room temperature for 13h. After the reaction is completed by monitoring with a thin layer plate, it is quenched with H2O, extracted with EAC, the organic phase is washed with saturated NaCl, and dried with anhydrous Na2SO4. The concentrated organic mixture is separated and purified by silica gel column chromatography to obtain a transparent oily intermediate 4 with a yield of 35%.

[0141] 1H NMR(400MHz,Chloroform-d)δ5.77(s,1H),5.40–5.32(m,1H),4.40–4.28(m,2H),3.49(t,J=6.1Hz,2H),2.22(p,J=6.8Hz,1H),2.1 3–2.04(m,4H),1.98–1.74(m,6H),1.64–1.55(m,4H),1.28(d,J=3.7Hz,3H),1.01(dd,J=6.9,3.4Hz,6H),0.83(s,3H); ESI-MS:m / z calcd for C22H33BrO2[M+H]+:409.17, found 409.2.

[0142] Synthesis of 2-(phenylamino)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A9)

[0143]

[0144] Weigh intermediate 4 (1 g, 2.44 mmol), potassium iodide (0.081 g, 0.488 mmol), potassium carbonate (1.01 g, 7.33 mmol), aniline (0.27 g, 2.93 mmol), add DMF (5 mL), and react at 45°C for 13 h. After the reaction is completed by monitoring with a thin layer plate, the mixture is quenched with H2O, extracted with EAC, the organic phase is washed with saturated NaCl, and dried with anhydrous Na2SO4. The concentrated organic mixture is separated and purified by silica gel column chromatography to obtain a light yellow oil A9 with a yield of 40%.

[0145] 1H NMR (400MHz, DMSO-d6) δ7.10–7.02(m,2H),6.58(d,J=7.9Hz,2H),6.52(t,J=7.2Hz,1H),5.70(s,1H),5 .27(s,1H),4.09(q,J=5.9Hz,2H),3.26(t,J=5.9Hz,2H),2.19(p,J=6.9Hz,1H),2.09–1.98(m,2H),1.9 2(s,1H),1.78(dd,J=19.1,10.7Hz,3H),1.65(dq,J=12.1,5.7,4.6Hz,2H),1.49(d,J=9.1Hz,2H),1.32 –1.20(m,2H),1.17(s,3H),1.07(dt,J=12.1,5.2Hz,2H),0.97(dd,J=6.9,1.9Hz,6H),0.73(s,3H); 13C NMR(101MHz,DMSO-d6)δ178.08,148.95,144.81,135.29,129.35,122.84,120.80,116.32,112.54,63.62,50.73,46 .37,45.14,41.92,38.12,37.01,34.73,34.49,27.31,25.53,22.40,21.79,21.18,18.06,17.20,14.23; ESI-MS:m / z calcd for C28H39NO2[M+H]+:422.30, found 422.4.

[0146] Example 10

[0147] Synthesis of 2-((4-fluorophenyl)amino)ethyl(1R,4aR,4bR,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A10)

[0148]

[0149] The synthesis of compound A10 was carried out by referring to the synthesis method of compound A9 to obtain yellow oil A10 with a yield of 63%.

[0150] 1H NMR(400MHz,Chloroform-d)δ6.88(t,J=8.7Hz,2H),6.61–6.51(m,2H),5.77(s,1H),5.32(d,J=6.1Hz,1H),4.23(t,J=5.5Hz,2H),3.34(t,J=5.5H z,2H),2.23(p,J=6.9Hz,1H),2.12–2.02(m,4H),1.95–1.69(m,6H),1.66 –1.51(m,4H),1.25(s,3H),1.02(dd,J=6.8,3.5Hz,6H),0.82(s,3H); 13C NMR(101MHz,Chloroform-d)δ145.51,122.33,120.36,115.84,115.62,113.93,113.85,63.13,51.00,46. 75,45.27,43.68,38.31,37.14,34.91,34.56,27.48,25.69,22.49,21.44,20.88,18.11,17.04,14.05; 19F NMR(376MHz,Chloroform-d)δ-25.20,-127.60(tt,J=8.6,4.5Hz); ESI-MS:m / z calcd for C28H38FNO2[M+H]+:440.29, found 440.01.

[0151] Embodiment 11

[0152] Synthesis of 2-(4-chlorophenyl)amino)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A11)

[0153]

[0154] The synthesis of compound A11 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid compound A11 with a yield of 47% and mp: 77.1-78.6°C.

[0155] 1H NMR(400MHz,Chloroform-d)δ7.12(d,J=8.8Hz,2H),6.55(d,J=8.7Hz,2H),5.77(s,1H),5.32(d,J=2.8Hz,1H),4.23(t,J=5.5Hz,2H),3.36(t,J=5.5Hz, 2H),2.23(p,J=6.6Hz,1H),2.11–2.02(m,4H),1.96–1.70(m,6H),1.62–1.5 4(m,4H),1.25(s,3H),1.02(dd,J=6.8,3.6Hz,6H),0.81(s,3H); ESI-MS:m / z calcd for C28H38ClNO2[M+H]+:456.26,found456.03.

[0156] Example 12

[0157] Synthesis of 2-(4-bromophenyl)amino)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A12)

[0158]

[0159] The synthesis of compound A12 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid compound A12 with a yield of 50% and mp: 80.4-82.3°C.

[0160] 1H NMR(400MHz,Chloroform-d)δ7.27(d,J=8.7Hz,2H),6.51(d,J=8.6Hz,2H),5.79(s,1H),5.33(s,1H),4.26(t,J=5.6Hz,2H),3.37(t,J=5.6Hz,2H),2 .26(p,J=6.7Hz,1H),2.14–2.02(m,4H),1.97–1.71(m,6H),1.60(d,J=4.2 Hz, 4H), 1.28 (s, 3H), 1.05 (dd, J=6.9, 3.3Hz, 6H), 0.84 (s, 3H); ESI-MS: m / z calcd for C28H38BrNO2[M+H]+:500.21, found 499.93.

[0161] Embodiment 13

[0162] Synthesis of 2-((4-iodophenyl)amino)ethyl(1R,4aR,4bR,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A13)

[0163]

[0164] The synthesis of compound A13 was carried out by referring to the synthesis method of compound A9 to obtain reddish brown solid compound A13 with a yield of 23% and mp: 76.7-77.8°C.

[0165] 1H NMR(400MHz,Chloroform-d)δ7.43(d,J=8.5Hz,2H),6.42(d,J=8.5Hz,2H),5.80(s,1H),5.39–5.29(m,1H),4.25(t,J=5.5Hz,2H),3.37(t,J=5.5Hz,2 H),2.26(p,J=6.8Hz,1H),2.15–2.04(m,4H),1.98–1.71(m,6H),1.66–1.54 (m,4H),1.28(s,3H),1.05(dd,J=6.9,3.4Hz,6H),0.84(s,3H); ESI-MS:m / z calcd for C28H38INO2[M+H]+:548.19, found 547.94.

[0166] Embodiment 14

[0167] Synthesis of 2-(p-Tolylamino)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A14)

[0168]

[0169] The synthesis of compound A14 was carried out by referring to the synthesis method of compound A9 to obtain brown solid compound A14 with a yield of 65% and mp: 60.6-61.9°C.

[0170] 1H NMR (400MHz, Chloroform-d) δ6.99(d,J=8.0Hz,2H),6.55(d,J=8.3Hz,2H),5.78(s,1H),5.34(d,J=6.2Hz,1H),4.23(t,J=5.5Hz,2H),3.36(t,J=5. 6Hz,2H),2.24(s,4H),2.11–2.02(m,4H),1.96–1.72(m,6H),1.66–1.52( m,4H),1.26(s,3H),1.02(dd,J=6.9,3.6Hz,6H),0.82(s,3H); ESI-MS:m / z calcd for C29H41NO2[M+H]+:436.31,found436.03.

[0171] Embodiment 15

[0172] Synthesis of 2-((4-methoxyphenyl)amino)ethyl(1R,4aR,4bR,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A15)

[0173]

[0174] The synthesis of compound A15 was carried out by referring to the synthesis method of compound A9 to obtain yellow oil A15 with a yield of 46%.

[0175] 1H NMR (400MHz, Chloroform-d) δ6.78(d,J=8.9Hz,2H),6.60(d,J=8.9Hz,2H),5.78(s,1H),5.34(d,J=6.0Hz,1H),4.23(t,J=5.5Hz,2H),3.75(s,3H),3.34(t ,J=5.5Hz,2H),2.23(p,J=6.7Hz,1H),2.12–2.04(m,4H),1.99–1.69(m,6H), 1.68–1.50(m,4H),1.26(s,3H),1.02(dd,J=6.9,3.6Hz,6H),0.83(s,3H); 13C NMR(101MHz,Chloroform-d)δ145.43,141.83,135.64,122.37,120.45,114.96,114.53,63.26,55.82,50.99,46.7 4,45.29,44.01,38.31,37.16,34.91,34.57,27.48,25.70,22.50,21.44,20.88,18.13,17.05,14.06; ESI-MS:m / z calcd for C29H41NO3[M+H]+:452.31, found 452.04.

[0176] Example 16

[0177] Synthesis of 2-(m-tolylamino)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A16)

[0178]

[0179] The synthesis of compound A16 was carried out by referring to the synthesis method of compound A9 to obtain a transparent oily substance A16 with a yield of 23%.

[0180] 1H NMR(400MHz,Chloroform-d)δ7.08(d,J=7.4Hz,1H),6.55(d,J=7.5Hz,1H),6.44(d,J=2.7Hz,2H) ,5.78(s,1H),5.38–5.30(m,1H),4.24(t,J=5.5Hz,2H),3.37(t,J=5.5Hz,2H),2.27(d,J=4.8Hz,4 H),2.25–2.19(m,1H),2.16–1.99(m,4H),1.91(dd,J=25.3,14.0Hz,2H),1.76(ddd,J=17.2,8.9, 4.4Hz, 3H), 1.64–1.53 (m, 4H), 1.26 (s, 3H), 1.01 (dd, J=6.8, 3.5Hz, 6H), 0.82 (s, 3H); ESI-MS: m / z calcd for C29H41NO2[M+H]+:436.31, found 436.02.

[0181] Embodiment 17

[0182] Synthesis of 2-(pyridine-4-thio)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A17)

[0183]

[0184] Weigh intermediate 4 (1 g, 2.44 mmol), potassium carbonate (1.01 g, 7.33 mmol) and mercaptopyridine (2.71 g, 2.44 mmol), add DMF (5 mL), and react at room temperature for 13 h. After the reaction is completed by monitoring with a thin layer plate, it is quenched with H2O, extracted with EAC, the organic phase is washed with saturated NaCl, and dried with anhydrous Na2SO4. The concentrated organic mixture is separated and purified by silica gel column chromatography to obtain the final product A17. It is a transparent oil with a yield of 55%.

[0185] 1H NMR(400MHz,Chloroform-d)δ8.41(d,J=6.3Hz,2H),7.21–7.18(m,2H),5.77(s,1H),5.37–5.32(m,1H),4.31–4.21(m,2H),3.21(t,J=7.0Hz,2H 13C NMR(101MHz,Chloroform-d)δ178.39,149.31,145.52,135.63,122.33,120.77,120.37,62.23,50.91,46.71,4 5.07,38.26,37.09,34.91,34.54,28.99,27.47,25.73,22.47,21.43,20.87,18.08,17.00,14.04; ESI-MS:m / z calcdfor C27H37NO2S[M+H]+:440.25, found 440.01.

[0186] Embodiment 18

[0187] Synthesis of 2-(1H-benzimidazol-2-yl)thio)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A18)

[0188]

[0189] The synthesis of compound A18 was carried out by referring to the synthesis method of compound A17 to obtain white solid A18 with a yield of 75% and mp: 66.0-67.9°C.

[0190] 1H NMR(400MHz,Chloroform-d)δ7.52(dd,J=6.0,3.1Hz,2H),7.22–7.17(m,2H),5.77(s,1H),5.38–5.31(m,1H),4.37(tt,J=6.5,3.7Hz,2H),3.47(t,J=6. 6Hz,2H),2.23(hept,J=7.4Hz,1H),2.12–1.99(m,4H),1.99–1.65(m,6H),1 .64–1.44(m,4H),1.24(s,3H),1.01(dd,J=6.9,3.2Hz,6H),0.81(s,3H); 13C NMR(101MHz,Chloroform-d)δ179.10,145.57,122.43,122.36,120.49,62.85,50.88,46.79,45.04,38 .19,37.16,34.92,34.54,30.98,27.45,25.76,22.47,21.43,20.85,18.08,17.00,14.06; ESI-MS:m / z calcd forC29H38N2O2S[M+H]+:479.27, found 479.00.

[0191] Embodiment 19

[0192] Synthesis of 2-(5-methyl-1H-benzimidazol-2-yl)thio)ethyl (1R,4aR,4bR,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A19)

[0193]

[0194] The synthesis of compound A19 was carried out by referring to the synthesis method of compound A17 to obtain white solid A19 with a yield of 77% and mp: 51.0-52.4°C.

[0195] 1H NMR (400MHz, Chloroform-d) δ7.42 (d, J = 7.7Hz, 1H), 7.30 (s, 1H), 7.03 (d, J = 8. 1Hz,1H),5.78(s,1H),5.36(s,1H),4.35(t,J=6.5Hz,2H),3.44(t,J=6.5Hz,2H ),2.45(s,3H),2.27–2.20(m,1H),2.07(t,J=9.0Hz,3H),1.95–1.71(m,6H),1. 58(d,J=14.1Hz,4H),1.25(d,J=9.0Hz,4H),1.05–1.00(m,6H),0.82(s,3H); 13C NMR(101MHz,Chloroform-d)δ148.17,145.59,135.72,132.33,123.86,122.35,120.53,62.81,50.88,46.78,45.0 2,38.18,37.16,34.92,34.54,31.14,27.46,25.76,22.48,21.64,21.44,20.87,18.09,17.01,14.08; ESI-MS:m / z calcd for C30H40N2O2S[M+H]+:493.28, found 493.01.

[0196] Embodiment 20

[0197] Synthesis of 2-(5-methoxy-1H-benzimidazol-2-yl)thio)ethyl (1R, 4aR, 4bR, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A20)

[0198]

[0199] The synthesis of compound A20 was carried out by referring to the synthesis method of compound A17 to obtain a transparent oily substance A20 with a yield of 80%.

[0200] 1H NMR(400MHz,Chloroform-d)δ7.40(s,1H),7.02(s,1H),6.85(d,J=8.8Hz,1H),5.78(s,1H),5.36(s,1H),4.36(td,J=6.4,2.4Hz,2H),3.8 4(s,3H),3.43(t,J=6.5Hz,2H),2.23(dt,J=13.3,6.7Hz,1H),2.08(d,J=10.2Hz,3H),1.98–1.69(m,6H),1.66–1.50(m,4H),1.25(d,J=9. 7Hz, 4H), 1.02 (dd, J = 6.8, 3.0Hz, 6H), 0.82 (s, 3H); 13CNMR (101MHz, Chloroform-d) δ 179.10, 156.31, 145.57, 135.68, 122.33, 120.52, 62 .82,55.85,50.89,46.78,45.03,38.19,37.18,34.91,34.54,31.33,27.46,25.75,22.47,21.43,20.86,18.09,17.01,14.07; ESI-MS: m / z calcd for C30H40N2O3S[M+H]+:509.28, found 508.97.

[0201] Embodiment 21

[0202] 2-(5-(Difluoromethoxy)-1H-benzimidazol-2-yl)thio)ethyl (1R,4aR,4bR,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylate (A21)

[0203]

[0204] The synthesis of compound A21 was carried out by referring to the synthesis method of compound A17 to obtain a transparent oily substance A21 with a yield of 69%.

[0205] 1H NMR(400MHz,Chloroform-d)δ7.47(d,J=8.2Hz,1H),7.31(s,1H),7.02(dd,J=8.6,2.0 Hz,1H),6.50(t,J=74.3Hz,1H),5.78(s,1H),5.36(s,1H),4.37(t,J=6.1Hz,2H),3.45( t,J=6.6Hz,2H),2.23(dt,J=13.2,6.3Hz,1H),2.10–2.04(m,3H),1.98–1.68(m,6H),1 .66–1.51(m,4H),1.25(d,J=11.2Hz,4H),1.02(dd,J=6.8,3.0Hz,6H),0.82(s,3H); 13C NMR(101MHz,Chloroform-d)δ179.34,145.71,135.75,122.29,120.41,116.47,115.42,62.76,50.90,46. 83,45.06,38.18,37.18,34.91,34.55,30.78,27.46,25.77,22.46,21.43,20.86,18.07,17.00,14.06; 19F NMR(376MHz,Chloroform-d)δ-80.12(d,J=3.8Hz),-80.32(d,J=3.8Hz); ESI-MS:m / zcalcd for C30H38F2N2O3S[M+Na]+:567.26, found 567.03.

[0206] Embodiment 22

[0207] Synthesis of (1R, 4aS, 10aR)-7-isopropyl-1, 4a-dimethyl-N-(4-(phenylamino)pyrimidin-2-yl)-1, 2, 3, 4, 4a, 9, 10, 10a-octahydrophenanthrene-1-carboxamide (B1)

[0208]

[0209] The synthesis of compound B1 was carried out by referring to the synthesis method of compound A1 to obtain light yellow solid B1 with a yield of 27% and mp: 105.6-106.9°C.

[0210] 1H NMR (400MHz, DMSO-d6) δ9.80(s,1H),9.59(s,1H),8.12(d,J=5.8Hz,1H),7.91(d,J= 7.9Hz,2H),7.28(t,J=7.9Hz,2H),7.19(d,J=8.1Hz,1H),6.98(t,J=7.8Hz,2H),6.86 (s,1H),6.49(d,J=5.8Hz,1H),2.80(dp,J=20.8,6.8Hz,3H),2.28(dd,J=33.6,12.4H z,2H),1.95–1.55(m,7H),1.25(d,J=10.9Hz,6H),1.15(d,J=6.8Hz,6H); ESI-MS:m / z calcd for C30H36N4O[M+H]+:469.29, found 469.05.

[0211] Embodiment 23

[0212] Synthesis of (1R, 4aS, 10aR)-N-(4-fluorophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxamide (B2)

[0213]

[0214] The synthesis of compound B2 was carried out by referring to the synthesis method of compound A1 to obtain light yellow solid B2 with a yield of 36% and mp: 100.3-102.7°C.

[0215] 1H NMR (400MHz, DMSO-d6) δ9.80 (s, 1H), 9.64 (s, 1H), 8.12 (d, J = 5.7Hz, 1H), 7.96 (dd ,J=9.0,5.0Hz,2H),7.19(d,J=8.1Hz,1H),7.11(t,J=8.8Hz,2H),6.99(d,J=8.0Hz ,1H),6.86(s,1H),6.46(d,J=5.8Hz,1H),2.80(ddt,J=20.5,13.5,6.8Hz,3H),2.2 8(dd,J=33.8,12.4Hz,2H),2.03–1.51(m,7H),1.26(s,3H),1.20–1.12(m,9H); 13C NMR(101MHz,Chloroform-d)δ176.43,157.38,156.79,146.80,145.84,134.67,126.94,125.00,124.92,124.09,123 19F NMR(376MHz,Chloroform-d)δ-116.52; ESI-MS:m / zcalcd for C31H38N4O[M+H]+:483.30, found 487.4.

[0216] Embodiment 24

[0217] Synthesis of (1R, 4aS, 10aR)-N-(4-chlorophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxamide (B3)

[0218]

[0219] The synthesis of compound B3 was carried out by referring to the synthesis method of compound A1 to obtain white solid B3 with a yield of 35% and mp: 107.2-108.7°C.

[0220] 1H NMR (400MHz, DMSO-d6) δ9.81 (s, 1H), 9.72 (s, 1H), 8.15 (d, J = 5.7Hz, 1H), 7.99 (d ,J=9.0Hz,2H),7.30(d,J=8.9Hz,2H),7.19(d,J=8.2Hz,1H),6.98(d,J=8.2Hz,1H ),6.86(s,1H),6.49(d,J=5.8Hz,1H),2.79(qt,J=13.4,6.8Hz,3H),2.28(dd,J=3 2.7,12.4Hz,2H),1.90–1.41(m,7H),1.26(s,3H),1.19–1.11(m,9H); ESI-MS:m / z calcd forC30H35ClN4O[M+H]+:503.25, found 503.4.

[0221] Embodiment 25

[0222] Synthesis of (1R, 4aS, 10aR)-N-(4-bromophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxamide (B4)

[0223]

[0224] The synthesis of compound B4 was carried out by referring to the synthesis method of compound A1 to obtain light yellow solid B4 with a yield of 36% and mp: 115.6-116°C.

[0225] 1H NMR (400MHz, DMSO-d6) δ9.87 (s, 1H), 9.75 (s, 1H), 8.15 (d, J = 5.7Hz, 1H), 7.94 (d ,J=8.6Hz,2H),7.43(d,J=8.8Hz,2H),7.19(d,J=8.2Hz,1H),6.98(d,J=8.1Hz,1H ),6.86(s,1H),6.49(d,J=5.8Hz,1H),2.77(dq,J=21.1,7.2,6.7Hz,2H),2.36–2 .20(m,2H),1.85–1.44(m,8H),1.33–1.20(m,6H),1.17–1.14(m,6H); ESI-MS:m / z calcd forC30H35BrN4O[M+H]+:547.20, found 547.4.

[0226] Embodiment 26

[0227] Synthesis of (1R, 4aS, 10aR)-N-(4-(4-iodophenylamino)pyrimidin-2-yl)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxamide (B5)

[0228]

[0229] The synthesis of compound B5 was carried out by referring to the synthesis method of compound A1 to obtain light yellow solid B5 with a yield of 18% and mp: 115.4-117.2°C.

[0230] 1H NMR (400MHz, DMSO-d6) δ9.82 (s, 1H), 9.70 (s, 1H), 8.15 (d, J = 5.8Hz, 1H), 7.80 (d, J = 8.9Hz ,2H),7.58(d,J=8.8Hz,2H),7.19(d,J=8.2Hz,1H),6.99(d,J=8.1Hz,1H),6.86(s,1H),6.4 9(d,J=5.8Hz,1H),2.80(ddt,J=20.5,13.8,6.8Hz,3H),2.28(dd,J=29.6,12.3Hz,2H),1. 94–1.71(m,3H),1.68–1.42(m,4H),1.25(d,J=11.2Hz,6H),1.17–1.15(m,6H); ESI-MS:m / z calcd for C30H35IN4O[M+H]+:595.19, found 594.79.

[0231] Embodiment 27

[0232] Synthesis of (1R, 4aS, 10aR)-7-isopropyl-1, 4a-dimethyl-N-(4-p-tolylamino)pyrimidin-2-yl)-1, 2, 3, 4, 4a, 9, 10, 10a-octahydrophenanthrene-1-carboxamide (B6)

[0233]

[0234] The synthesis of compound B6 was carried out by referring to the synthesis method of compound A1 to obtain light yellow solid B6 with a yield of 25% and mp: 99.3-100.7°C.

[0235] 1H NMR (400MHz, DMSO-d6) δ9.74 (s, 1H), 9.49 (s, 1H), 8.09 (d, J = 5.8Hz, 1H), 7.77 (d, J=7.5Hz,2H),7.19(d,J=8.2Hz,1H),7.10(d,J=8.0Hz,2H),6.99(d,J=8.0Hz,1H), 6.86(s,1H),6.45(d,J=5.8Hz,1H),2.86–2.74(m,3H),2.28(d,J=15.0Hz,5H),2.0 7–1.96(m,1H),1.80–1.58(m,6H),1.26(s,3H),1.16(d,J=6.8Hz,9H); ESI-MS:m / z calcd forC31H38N4O[M+H]+:483.30, found 483.4.

[0236] Embodiment 28

[0237] Synthesis of (1R, 4aS, 10aR)-7-isopropyl-1, 4a-dimethyl-N-(4-p-tolylamino)pyrimidin-2-yl)-1, 2, 3, 4, 4a, 9, 10, 10a-octahydrophenanthrene-1-carboxamide (B7)

[0238]

[0239] The synthesis of compound B7 was carried out by referring to the synthesis method of compound A1 to obtain yellow solid B7 with a yield of 15% and mp: 112.4-114.7°C.

[0240] 1H NMR (400MHz, DMSO-d6) δ9.72(s,1H),9.43(s,1H),8.06(d,J=5.8Hz,1H),7.78(d,J= 8.5Hz,2H),7.19(d,J=8.2Hz,1H),6.98(d,J=10.0Hz,1H),6.86(d,J=9.0Hz,3H),6. 40(d,J=5.9Hz,1H),3.73(s,3H),2.80(tq,J=13.9,6.7Hz,3H),2.27(dd,J=28.7,11 .4Hz,2H),1.89–1.65(m,4H),1.60–1.44(m,3H),1.26(s,3H),1.18–1.13(m,9H).13C NMR(101MHz,Chloroform-d)δ176.43,157.38,156.79,146.80,145.84,134.67,126.94,125.00,124.92,124.09,123.97, 116.45,116.22,99.53,48.90,45.30,37.82,37.19,37.15,33.48,29.93,25.27,24.00,21.39,18.77,16.68; ESI-MS:m / z calcd forC31H38N4O2[M+H]+:499.30, found 499.03.

[0241] Embodiment 29

[0242] Synthesis of (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-N-(4-m-tolylamino)pyrimidin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxamide (B8)

[0243]

[0244] The synthesis of compound B8 was carried out by referring to the synthesis method of compound A1 to obtain white solid B8 with a yield of 33% and mp: 106.9-109.3°C.

[0245] 1H NMR (400MHz, DMSO-d6) δ9.80 (s, 1H), 9.52 (s, 1H), 8.11 (d, J = 5.8Hz, 1H), 7.9 9(s,1H),7.55(d,J=10.1Hz,1H),7.17(dd,J=17.2,8.0Hz,2H),6.99(d,J=8.1 Hz,1H),6.86(s,1H),6.80(d,J=7.5Hz,1H),6.48(d,J=5.8Hz,1H),2.88–2.7 0(m,3H),2.31(s,5H),1.91–1.49(m,7H),1.27(s,3H),1.19–1.13(m,9H); 13C NMR(101MHz,Chloroform-d)δ161.85,157.01,145.82,139.59,134.71,129.31,126.95,126.03,124.09,123.95,123.33 ,119.68,99.68,48.85,45.34,37.86,37.28,37.16,33.48,29.95,25.30,24.00,21.45,21.40,18.78,16.72; ESI-MS: m / z calcd for C31H38N4O[M+H]+:483.30, found 483.4.

[0246] Embodiment 30

[0247] Synthesis of 2-(phenylamino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B9)

[0248] Synthesis of 2-bromoethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (6)

[0249]

[0250] The synthesis of compound 6 was carried out by referring to the synthesis method of compound 4 to obtain a transparent oily substance 6 with a yield of 26%.

[0251] 1H NMR(400MHz,Chloroform-d)δ7.19(d,J=8.1Hz,1H),7.03(d,J=8.1Hz,1H),6.91(s,1H),4.40(ddt,J=41.9,11.9,5.9Hz,2H),3.52(t,J=5 .8Hz,2H),3.03–2.78(m,3H),2.37–2.25(m,2H),1.93–1.62(m,6H),1.49–1.42(m,1H),1.31(s,3H),1.25(s,3H),1.23(s,6H); ESI-MS: m / z calcd for C22H31BrO2[M+H]+:407.15, found 406.87.

[0252] Synthesis of 2-(phenylamino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B9)

[0253]

[0254] The synthesis of compound B9 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid B9 with a yield of 45% and mp: 102.7-104.6°C.

[0255] 1H NMR(400MHz,Chloroform-d)δ7.21–7.11(m,3H),7.00(dd,J=8.2,2.1Hz,1H),6.87(s,1H),6.71(t ,J=7.3Hz,1H),6.61(dd,J=8.7,1.1Hz,2H),4.39–4.18(m,2H),3.39(t,J=5.5Hz,2H),2.91–2.73( m,3H),2.30(dd,J=13.6,2.5Hz,1H),2.24(dd,J=12.5,2.2Hz,1H),1.88–1.68(m,4H),1.63(dd,J= 6.7, 2.3Hz, 1H), 1.51 (dd, J=12.6, 4.0Hz, 1H), 1.43–1.36 (m, 1H), 1.29–1.19 (m, 12H); ESI-MS: m / z calcd for C28H37NO2[M+H]+:420.28, found 419.99.

[0256] Embodiment 31

[0257] Synthesis of 2-(4-fluorophenyl)amino)ethyl (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B10)

[0258]

[0259] The synthesis of compound B10 was carried out by referring to the synthesis method of compound A9 to obtain yellow solid B10 with a yield of 47% and mp: 88.6-90.9°C.

[0260] 1H NMR (400MHz, DMSO-d6) δ7.15(d,J=8.0Hz,1H),6.97(d,J=8.2Hz,1H),6.82(d,J =6.9Hz,3H),6.57(dd,J=6.1,3.4Hz,2H),4.12(dp,J=22.7,5.9Hz,2H),3.26(d, J=6.1Hz,2H),2.83–2.67(m,3H),2.28(d,J=12.9Hz,1H),2.06(d,J=12.2Hz,1H) ,1.88–1.43(m,7H),1.28(d,J=14.0Hz,3H),1.19–1.15(m,6H),1.12(s,3H); 13C NMR(101MHz,Chloroform-d)δ178.70,146.82,134.54,126.93,124.18,124.02,115.87,115.65,113.87,113 19F NMR (376MHz, Chloroform-d) δ-127.49; ESI-MS: m / z calcd forC28H36FNO2[M+H]+: 438.27, found438.08.

[0261] Embodiment 32

[0262] Synthesis of 2-((4-chlorophenyl)amino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B11)

[0263]

[0264] The synthesis of compound B11 was carried out by referring to the synthesis method of compound A9 to obtain yellow solid B11 with a yield of 55% and mp: 86.3-88.6°C.

[0265] 1H NMR(400MHz,Chloroform-d)δ7.16(d,J=8.2Hz,1H),7.12–7.07(m,2H),7.01(dd,J=8.2,2.1Hz,1H),6.86(d ,J=2.0Hz,1H),6.57–6.49(m,2H),4.27(ddt,J=36.3,11.2,5.5Hz,2H),3.35(t,J=5.5Hz,2H),2.82(q,J=9.0 ,7.9Hz,3H),2.30(dt,J=10.8,2.3Hz,1H),2.22(dd,J=12.5,2.2Hz,1H),1.88–1.79(m,1H),1.78–1.72(m,2H ),1.71–1.60(m,2H),1.52–1.44(m,1H),1.37(ddt,J=13.0,5.6,2.5Hz,1H),1.28–1.19(m,12H); ESI-MS:m / z calcd for C28H36ClNO2[M+H]+:454.24, found 453.97.

[0266] Embodiment 33

[0267] Synthesis of 2-((4-bromophenyl)amino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B12)

[0268]

[0269] The synthesis of compound B12 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid B12 with a yield of 33% and mp: 78.6-80.2°C.

[0270] 1H NMR(400MHz,Chloroform-d)δ7.23(d,J=8.7Hz,2H),7.17(d,J=8.1Hz,1H),7.01( d,J=10.1Hz,1H),6.87(s,1H),6.48(d,J=8.7Hz,2H),4.27(ddt,J=37.5,11.2,5.4 Hz,2H),3.35(t,J=5.5Hz,2H),2.89–2.76(m,3H),2.26(dd,J=30.7,12.4Hz,2H), 1.88–1.65(m,5H),1.55–1.39(m,2H),1.27(s,3H),1.24–1.19(m,9H); ESI-MS:m / z calcdfor C28H36BrNO2[M+H]+:498.19, found 499.93.

[0271] Embodiment 34

[0272] Synthesis of 2-((4-iodophenyl)amino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B13)

[0273]

[0274] The synthesis of compound B13 was carried out by referring to the synthesis method of compound A9 to obtain yellow oil B13 with a yield of 35%.

[0275] 1H NMR(400MHz,Chloroform-d)δ7.39(d,J=8.7Hz,2H),7.16(d,J=8.2Hz,1H),7.01(dd,J=8.1,2. 1Hz,1H),6.87(s,1H),6.42–6.35(m,2H),4.26(ddt,J=36.2,11.2,5.5Hz,2H),3.34(t,J=5.5H z,2H),2.90–2.72(m,3H),2.34–2.16(m,2H),1.87–1.78(m,1H),1.77–1.66(m,3H),1.65–1.60 (m,1H),1.48(td,J=13.0,12.1,3.8Hz,1H),1.39–1.33(m,1H),1.27–1.19(m,12H); ESI-MS:m / z calcd for C28H36INO2[M+H]+:546.18,found545.88.

[0276] Embodiment 35

[0277] Synthesis of 2-(p-Tolylamino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B14)

[0278]

[0279] The synthesis of compound B14 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid B14 with a yield of 50% and mp: 60.5-62.8°C.

[0280] 1H NMR(400MHz,Chloroform-d)δ7.16(d,J=8.1Hz,1H),7.03–6.94(m,3H),6.87(d, J=2.0Hz,1H),6.60–6.50(m,2H),4.37–4.16(m,2H),3.36(t,J=5.5Hz,2H),2.89 –2.76(m,3H),2.36–2.18(m,5H),1.88–1.79(m,1H),1.78–1.67(m,3H),1.66–1. 61(m,1H),1.53–1.45(m,1H),1.43–1.37(m,1H),1.28–1.19(m,12H); ESI-MS:m / z calcd for C29H39NO2[M+H]+:434.30, found 434.08.

[0281] Embodiment 36

[0282] Synthesis of 2-((4-methoxyphenyl)amino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B15)

[0283]

[0284] The synthesis of compound 152 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid B15 with a yield of 52% and mp: 56.7-58.8°C.

[0285] 1H NMR(400MHz,Chloroform-d)δ7.17(d,J=8.1Hz,1H),7.00(d,J=8.1Hz,1H),6.87(s ,1H),6.77(d,J=8.8Hz,2H),6.59(d,J=6.6Hz,2H),4.26(ddt,J=33.8,11.2,5.5Hz ,2H),3.74(s,3H),3.34(t,J=5.5Hz,2H),2.88–2.76(m,3H),2.27(dd,J=25.8,12. 3Hz,2H),1.90–1.67(m,5H),1.52–1.38(m,2H),1.27(s,3H),1.24–1.19(m,9H); 13C NMR(101MHz,Chloroform-d)δ178.65,145.80,141.65,134.59,126.95,124.19,123.99,114.97,114.48,63.30, 55.82,47.78,44.93,44.12,37.97,36.96,36.65,33.48,30.09,25.17,24.01,21.77,18.59,16.56; ESI-MS:m / z calcd for C29H39NO3[M+H]+:450.29, found 450.05.

[0286] Embodiment 37

[0287] Synthesis of 2-(m-tolylamino)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B16)

[0288]

[0289] The synthesis of compound B12 was carried out by referring to the synthesis method of compound A9 to obtain light yellow solid B16 with a yield of 55% and mp: 86.5-88.5°C.

[0290] 1H NMR (400MHz, Chloroform-d) δ7.17(d,J=8.2Hz,1H),7.05(t,J=8.0Hz,1H),7.00(dd,J=8.2,2. 0Hz,1H),6.87(s,1H),6.54(d,J=8.9Hz,1H),6.43(d,J=7.8Hz,2H),3.37(t,J=5.5Hz,2H),2.87 –2.78(m,3H),2.32–2.22(m,5H),1.82(ddd,J=12.5,9.4,4.0Hz,1H),1.78–1.68(m,3H),1.66– 1.61(m,1H),1.53–1.45(m,1H),1.43–1.36(m,1H),1.28(s,3H),1.24–1.20(m,9H); ESI-MS:m / z calcd for C29H39NO2[M+H]+:434.30,found436.08.

[0291] Embodiment 38

[0292] Synthesis of 2-(pyridine-4-thio)ethyl (1R, 4aS, 10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B17)

[0293]

[0294] The synthesis of compound B17 was carried out by referring to the synthesis method of compound A17 to obtain white solid B17 with a yield of 59% and mp: 80.5-82.3°C.

[0295] 1H NMR(400MHz,Chloroform-d)δ8.36(d,J=5.6Hz,2H),7.20–7.13(m,3H),7.01(d, J=8.1Hz,1H),6.89(s,1H),4.39–4.22(m,2H),3.21(td,J=6.9,3.7Hz,2H),2.93 –2.79(m,3H),2.29(d,J=12.1Hz,1H),2.20(d,J=12.5Hz,1H),1.82(ddd,J=30.5 ,14.8,7.0Hz,2H),1.74–1.61(m,3H),1.47–1.38(m,2H),1.28–1.20(m,12H); 13C NMR(101MHz,Chloroform-d)δ178.42,149.38,147.98,146.79,145.84,134.55,126.91,124.23,124.04,120.72 ,62.28,47.78,44.71,37.88,36.91,36.49,33.49,30.04,29.06,25.16,24.03,21.80,18.54,16.49; ESI-MS:m / z calcd for C27H35NO2S[M+H]+:438.24, found 437.95.

[0296] Embodiment 39

[0297] Synthesis of 2-(1H-benzimidazol-2-yl)thio)ethyl (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B18)

[0298]

[0299] The synthesis of compound B18 was carried out by referring to the synthesis method of compound A18 to obtain white solid B18 with a yield of 69% and mp: 73.2-74.2°C.

[0300] 1H NMR(400MHz,Chloroform-d)δ7.49(s,2H),7.23–7.14(m,3H),7.02(d,J=8.1Hz,1H ),6.88(s,1H),4.41(tt,J=11.6,5.9Hz,2H),3.48(td,J=6.4,2.2Hz,2H),2.88(ddt ,J=28.1,13.7,6.5Hz,3H),2.33–2.19(m,2H),1.80(ddd,J=31.5,15.3,7.8Hz,3H), 1.65(dd,J=16.1,5.5Hz,2H),1.44(dd,J=13.0,6.9Hz,2H),1.28–1.20(m,12H); 13C NMR(101MHz,Chloroform-d)δ179.16,148.91,146.83,145.86,134.63,126.93,124.28,124.03,122.47,63. 03,47.85,44.80,37.85,36.94,36.59,33.50,31.08,30.08,25.19,24.03,21.82,18.53,16.49; ESI-MS:m / z calcd for C29H36N2O2S[M+H]+:477.25,found476.98.

[0301] Embodiment 40

[0302] Synthesis of 2-(5-methyl-1H-benzimidazol-2-yl)thio)ethyl (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B19)

[0303]

[0304] The synthesis of compound B19 was carried out by referring to the synthesis method of compound A18 to obtain white solid B19 with a yield of 65% and mp: 71.7-72.6°C.

[0305] 1H NMR(400MHz,Chloroform-d)δ7.48–7.34(m,1H),7.29(s,1H),7.16(d,J=8.2Hz,1 H),7.02(d,J=8.1Hz,2H),6.88(s,1H),4.48–4.33(m,2H),3.45(td,J=6.4,2.3Hz, 2H),2.85(dh,J=20.5,6.9Hz,3H),2.44(s,3H),2.25(t,J=13.8Hz,2H),1.90–1.7 3(m,3H),1.69–1.61(m,2H),1.44(dd,J=13.1,6.7Hz,2H),1.28–1.20(m,12H); 13C NMR(101MHz,Chloroform-d)δ179.15,146.84,145.84,134.64,132.34,126.94,124.26,124.02,123.88,63.03, 47.85,44.79,37.85,36.94,36.59,33.50,31.24,30.08,25.19,24.02,21.81,21.64,18.54,16.49; ESI-MS:m / z calcd for C30H38N2O2S[M+H]+:491.27, found 490.96.

[0306] Embodiment 41

[0307] Synthesis of 2-((5-methoxy-1H-benzimidazol-2-yl)thio)ethyl (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B20)

[0308]

[0309] The synthesis of compound B20 was carried out by referring to the synthesis method of compound A18 to obtain white solid B20 with a yield of 66% and mp: 63.2-65.2°C.

[0310] 1H NMR(400MHz,Chloroform-d)δ7.38(d,J=7.4Hz,1H),7.17(d,J=8.1Hz,1H),7.06–6.92(m,2H),6.89(s,1H),6.84(d,J=8.8Hz,1H),4.39(tq,J=11 .8,6.4Hz,2H),3.83(s,3H),3.43(h,J=7.7,6.1Hz,2H),2.88(dqt,J=20 .6,13.7,7.1Hz,3H),2.26(t,J=13.8Hz,2H),1.90–1.73(m,3H),1.69–1. 62(m,2H),1.45(dd,J=12.3,7.3Hz,2H),1.28–1.20(m,12H);13CNMR(101MHz,Chloroform-d)δ179.17,156.34,146.84,145.86,134.64,126.93, 124.27,124.02,111.78,62.98,55.85,47.86,44.80,37.86,36.94,36. 60,33.49,31.48,30.07,25.18,24.02,21.81,18.54,16.49; ESI-MS:m / z calcd for C30H38N2O3S[M+H]+:507.26, found 506.98.

[0311] Embodiment 42

[0312] Synthesis of 2-((5-(difluoromethoxy)-1H-benzimidazol-2-yl)thio)ethyl (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylate (B21)

[0313]

[0314] The synthesis of compound B21 was carried out by referring to the synthesis method of compound A18 to obtain white solid B21 with a yield of 68% and mp: 59.3-62.9°C.

[0315] 1H NMR(400MHz,Chloroform-d)δ7.42(s,1H),7.27(s,1H),7.16(d,J=8.2Hz,1H),7.02(td,J=8.5,7.9,2.1Hz,2H),6.89(d,J=2.0Hz,1H),6.49(t,J=74.3Hz, 1H),4.40(hept,J=6.3,5.7Hz,2H),3.56–3.38(m,2H),2.99–2.78(m,3H),2. 31–2.18(m,2H),1.91–1.73(m,3H),1.69–1.62(m,2H),1.47–1.36(m,2H); 13C NMR(101MHz,Chloroform-d)δ179.32,146.81,145.91,134.57,126.91,124.30,124.07,115.46,62.97,47.89,44.81,37.83,36. 92,36.57,33.50,30.93,30.06,25.15,24.02,21.82,18.51,16.47; 19FNMR (376MHz, Chloroform-d)δ-80.13,-80.33; ESI-MS: m / z calcd for C30H36F2N2O3S[M+H]+:543.24, found 542.95.

[0316] Embodiment 43

[0317] Determination of the antiproliferative activity of compounds on glioma cells

[0318] Experimental methods:

[0319] The CCK-8 method was used to investigate the antiproliferative activity of rosin acid derivatives A1-A21 and B1-B21 on human brain astroglioma cells U87MG and the toxicity of the derivatives with outstanding activity on normal liver cell L-02 cell line. Currently, the CCK-8 method (Cell Counting Kit-8) is one of the most common standard methods for detecting in vitro cell proliferation and toxicity experiments. Temozolomide (TMZ) was used as a positive control in the experiment to obtain the half-maximal inhibitory concentration (IC50 value) of different compounds on human brain glioma cells. The results are shown in Table 1.

[0320] Table 1 Antiproliferative activity of target compounds on U87MG cells (IC50, μM)

[0321]

[0322]

[0323] As can be seen from the table, among the 28 diterpene derivatives of rosin with detected activity, 27 compounds had better in vitro anti-proliferative activity (32 μM < IC50 < 808 μM) against U87MG cells than the positive control TMZ (IC50 = 937.2 μM). Generally, the anti-proliferative activity of the B series of dehydroabietic acid derivatives was higher than that of the A series of abietic acid derivatives. The end products obtained by condensing the primary amine of the N4-phenylpyrimidine-2,4-diamine intermediate with the carboxyl amide at the C18 position of the parent nucleus had obvious inhibitory effects on the proliferation of U87MG cells (50 μM < IC50 < 181 μM). The anti-proliferative activity of the alkyl side chain derivatives obtained by esterification and N-alkylation of the abietic acid-based parent nucleus with a benzene ring was poor (IC50 values were all greater than 170 μM), while the anti-proliferative activity of the alkyl side chain derivatives obtained by esterification and S-alkylation of the abietic acid-based parent nucleus with pyridine and benzimidazole was better (32 μM < IC50 < 268 μM). The intermediate rosin alkyl bromides 4 and 6 also showed certain anti-proliferative activity against U87MG.

[0324] Among these detected compounds, the activities of B3, B8, B17, B19, and B21 were relatively prominent, with IC50 values between 32 μM and 72 μM. Among them, the compound B21 with an IC50 value of 32.87 μM had the best activity. In order to screen out anti-glioma drugs with high efficiency and low toxicity, this study continued to further study the representative compounds with prominent activity and detected their cytotoxicity to human normal liver cells L-02. The experimental results are shown in Table 2.

[0325] Table 2 Toxicity of B3, B8, B17, B19, and B21 to normal liver cells (IC50, μM)

[0326]

[0327]

[0328] According to Table 2, it was significantly found that B19 and B21 showed higher safety, while B3, B8, and B17 might damage normal liver cells while exerting anti-glioma efficacy.

[0329] Example 44

[0330] Time-dependent and concentration-dependent study of the representative compound B21 on U87MG

[0331] Experimental method: U87MG cells were treated with different concentrations of compound B21 for 24 h, 48 h, and 72 h respectively, and then the cell viability was detected by the CCK-8 method. The time-dependent and concentration-dependent effects on U87MG are as Figure 1 shown.

[0332] According to Figure 1 ,it is shown that the inhibitory effect of compound B21 on the proliferation of U87MG cells shows a certain concentration dependence and time dependence.

[0333] Example 45

[0334] Determination of pKa value of representative compounds

[0335] Experimental method: Prepare the stock solution of representative compounds (acetonitrile, 1 mM, 5 mL), acetonitrile aqueous solution (Vacetonitrile:Vwater = 3:7, 50 mL), KCl solution (water, 0.15 M, 10 mL), KOH solution (Vacetonitrile:Vwater = 3:7, 60 mM, 10 mL), and HCl solution (Vacetonitrile:Vwater = 3:7, 100 mM, 10 mL) for standby; Add 10 mL of the prepared acetonitrile aqueous solution to a 15 mL beaker, measure its pH using a pH meter, and record the value after the reading stabilizes; Add 1 mL of the stock solution to this solution, measure and record the pH, and soak the probe in absolute ethanol for 30 min; Take another 10 mL of acetonitrile aqueous solution into a 25 mL beaker, measure its pH value, add 1 mL of KCl solution, stir evenly and then measure the pH; Adjust the pH to 2.0 using 100 mM HCl solution, then add 1 mL of the stock solution, wait until the solution is fully stirred evenly, and slowly titrate the above solution with 60 mM KOH solution, recording the change in pH value; The experimental data is processed and the pH-VKOH is plotted using Origin2022 software. Compounds B3, B8, B17, B19, and B21 are used as representatives for testing, and the results of the remaining compounds are similar.

[0336] The results are shown in Table 3 and Figure 2 ,it can be seen that the pKa values of representative compounds B3, B8, B17, B19, and B21 are 6.24 - 7.06, all within the ideal parameter range. According to Lipinski's five principles, the pKa of small molecule compounds that can improve BBB permeability needs to be within the range of 6 < pKa < 10.5, and the possibility of compounds with pKa < 8 becoming substrates of P-glycoprotein (P-gp) is extremely small, indicating that these target compounds may have good blood-brain barrier permeability to enter the brain and exert their pharmacological effects.

[0337] Table 3 pKa of representative compounds

[0338]

[0339] The specific embodiments described above further elaborate on the purpose, technical solutions, and beneficial effects of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements, and improvements made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims

1. A rosin acid derivative, characterized in that: The rosin acid derivatives have a structure of Formula I or Formula II: in, R is R1 is selected from hydrogen, halogen, methoxy or methyl; R2 is selected from hydrogen, halogen, methoxy or methyl; R3 is selected from hydrogen, methyl, methoxy or difluoromethoxy.

2. The rosin acid derivative according to claim 1, characterized in that: R is one of the following:

3. The method for preparing abietic acid derivatives according to claims 1 to 2, characterized in that: The steps include: S1, using AA as a starting material, undergoing an acylation reaction in the presence of an acylating agent and a polar organic solvent to obtain compound 1, and then undergoing an amide condensation reaction with one of the anilinopyrimidine compounds 2a-2h in the presence of an acid-binding agent and a polar organic reagent to obtain compounds A1-A8; S2, using DHAA as a starting material, an acylation reaction is carried out under the action of an acylating agent and a polar organic solvent to obtain compound 3, and then an amide condensation reaction is carried out with one of the anilinopyrimidine compounds 2a-2h under the action of an acid-binding agent and a polar organic reagent to obtain compounds B1-B8; S3, using AA as a starting material, an alkylation reaction is carried out under the action of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, and then an N-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and one of aniline compounds 5a-5h to obtain compounds A9-A16; S4, using DHAA as a starting material, an alkylation reaction is carried out under the action of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 6, and then an N-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and one of aniline compounds 5a-5h to obtain compounds B9-B16; S5, using AA as a starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, and then an S-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and a pyridine compound 7 to obtain compound A17; S6, using DHAA as a starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 6, and then an S-alkylation reaction is carried out with an alkaline reagent, a polar organic reagent and a pyridine compound 7 to obtain compound B17; S7, using AA as a starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, which is then subjected to an S-alkylation reaction with an alkaline reagent, a polar organic reagent and benzimidazole compounds 8a-8d to obtain compounds A18-A21; S8. Using DHAA as the starting material, an alkylation reaction is carried out in the presence of 1,2-dibromoethane, an alkaline reagent and a polar organic solvent to obtain compound 4, which is then subjected to an S-alkylation reaction with an alkaline reagent, a polar organic reagent and benzimidazole compounds 8a-8d to obtain compounds B18-B21.

4. The preparation method according to claim 3, characterized in that: The acylating agent is selected from one or more of oxalyl chloride, thionyl chloride and diphenylcarbamoyl chloride.

5. The preparation method according to claim 3, characterized in that: The acid binding agent is selected from one or more of triethylamine, pyridine and N,N-diisopropylethylamine.

6. The preparation method according to claim 3, characterized in that: The alkaline agent is selected from one or more of potassium carbonate, triethylamine and N,N-diisopropylethylamine.

7. The preparation method according to claim 3, characterized in that: The equivalent ratio of AA or DHAA to the acylating agent is 1:1.5-1.8; the acylation reaction occurs at a reaction temperature of 0°C to room temperature to generate compound 1 or compound 3.

8. The preparation method according to claim 7, characterized in that:The compound 1 or compound 3 and the compound One of the above undergoes an amide condensation reaction, the reaction temperature is room temperature, and the reaction time is 16-18 hours.

9. The preparation method according to claim 3, characterized in that: The equivalent ratio of AA or DHAA to 1,2-dibromoethane is 1:2-2.5; an alkylation reaction occurs at room temperature to generate compound 4 or compound 6.

10. Use of the rosin acid derivatives or pharmaceutically acceptable salts thereof according to claim 1 or 2 in the preparation of anti-glioma drugs.

Citation Information

Patent Citations

  • Oxazolidinone dehydroabietate derivative as well as preparation method and application thereof

    CN108299330A

  • Pyrimidine dehydroabietate derivatives and preparation method and application thereof

    CN111253323A

  • Rosin diterpenoid compound as well as preparation method and application thereof

    CN115073361A